202 related articles for article (PubMed ID: 11350879)
1. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
Wagner U; Köhler S; Reinartz S; Giffels P; Huober J; Renke K; Schlebusch H; Biersack HJ; Möbus V; Kreienberg R; Bauknecht T; Krebs D; Wallwiener D
Clin Cancer Res; 2001 May; 7(5):1154-62. PubMed ID: 11350879
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
3. Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res., 7: 1154-1162, 2001.
Foon KA; Bhattacharya-Chatterjee M
Clin Cancer Res; 2001 May; 7(5):1112-5. PubMed ID: 11350872
[No Abstract] [Full Text] [Related]
4. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report.
Reinartz S; Boerner H; Koehler S; Von Ruecker A; Schlebusch H; Wagner U
Hybridoma; 1999 Feb; 18(1):41-5. PubMed ID: 10211787
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
[TBL] [Abstract][Full Text] [Related]
8. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
[TBL] [Abstract][Full Text] [Related]
9. [A trial with immunotherapy of ovarian cancer by idiotype vaccination. Activation of the idiotype network in patients with advanced ovarian cancers by treatment with monoclonal antibody OC125].
Wagner U; Reinsberg J; Krebs D
Geburtshilfe Frauenheilkd; 1990 Oct; 50(10):785-8. PubMed ID: 2286317
[TBL] [Abstract][Full Text] [Related]
10. [Immuno-therapeutic study of anti-idiotype minibody (single chain Fv-CH3) on ovarian carcinoma bearing mice].
Li Y; Chang XH; Cui H; Yang WL; Feng J; Wei LH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):451-6. PubMed ID: 12974094
[TBL] [Abstract][Full Text] [Related]
11. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen.
Foon KA; Oseroff AR; Vaickus L; Greenberg SJ; Russell D; Bernstein Z; Pincus S; Köhler H; Seon BK; Tahaoglu E
Clin Cancer Res; 1995 Nov; 1(11):1285-94. PubMed ID: 9815923
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network.
Wagner UA; Oehr PF; Reinsberg J; Schmidt SC; Schlebusch HW; Schultes B; Werner A; Prietl G; Krebs D
Biotechnol Ther; 1992; 3(1-2):81-9. PubMed ID: 1305894
[TBL] [Abstract][Full Text] [Related]
14. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
[TBL] [Abstract][Full Text] [Related]
15. Construction and expression of a single chain antibody mimicing human ovarian cancer antigen CA125.
Li AD; Li Z; Wang YH; Zhang YM; Ma J
Cell Mol Immunol; 2006 Feb; 3(1):59-62. PubMed ID: 16549051
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
[TBL] [Abstract][Full Text] [Related]
17. [The study of immunotherapy of ovarian carcinoma with anti-idiotypic antibody].
Wang J; Qian H; Feng J
Zhonghua Fu Chan Ke Za Zhi; 1996 Jun; 31(6):353-6. PubMed ID: 9206171
[TBL] [Abstract][Full Text] [Related]
18. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody.
Robins RA; Denton GW; Hardcastle JD; Austin EB; Baldwin RW; Durrant LG
Cancer Res; 1991 Oct; 51(19):5425-9. PubMed ID: 1913661
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Sabbatini P; Dupont J; Aghajanian C; Derosa F; Poynor E; Anderson S; Hensley M; Livingston P; Iasonos A; Spriggs D; McGuire W; Reinartz S; Schneider S; Grande C; Lele S; Rodabaugh K; Kepner J; Ferrone S; Odunsi K
Clin Cancer Res; 2006 Sep; 12(18):5503-10. PubMed ID: 17000686
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).
Reinartz S; Köhler S; Schlebusch H; Krista K; Giffels P; Renke K; Huober J; Möbus V; Kreienberg R; DuBois A; Sabbatini P; Wagner U
Clin Cancer Res; 2004 Mar; 10(5):1580-7. PubMed ID: 15014007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
